scholarly journals Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

2013 ◽  
Vol 37 (11) ◽  
pp. 1514-1514 ◽  
Author(s):  
T A Wadden ◽  
◽  
P Hollander ◽  
S Klein ◽  
K Niswender ◽  
...  
Keyword(s):  
Weight Loss ◽  
Weight Maintenance ◽  
Randomized Study ◽  
Low Calorie ◽  
Additional Weight ◽  
Low Calorie Diet ◽  
Calorie Diet

scholarly journals Vegan or Low Calorie Diet for Weight Loss in Polycystic Ovary Syndrome Females: A Randomised Controlled Study

2020 ◽  
Vol 14 (1-2) ◽  
Author(s):  
Shubhra Saraswat
Keyword(s):  
Weight Loss ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Randomized Study ◽  
Vegan Diet ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

ABSTRACT The primary aim of this randomized study is to find the effect of a diet based intervention (vegan diet and low-calorie diet) among women suffering from polycystic ovary syndrome (PCOS). Overweight and obese (BMI- 33.7 ± 4.8 kg/m2) women with PCOS (n = 21; age, 33.1 ± 4.4 years) were assessed to participate in a 90 days randomized weight loss study delivered and guided through diet and nutrition counseling (personalized and group). Body weight, BMI and waist circumference and dietary intakes were assessed three times at 0, 45 and 90 days. It was hypothesized that weight loss would be more in the vegan group. All data were statistically analyzed and presented as median (inter quartile range). Vegan participants reported significant weight loss at Day 90, “1.8% (“5.0%, “0.9%) vegan, 0.0% (“1.2%, 0.3%) low-cal; P = .04), Vegan participants showed a greater decrease in energy (“265 (“469, 0)) kcal/d) and fat intake “8.2% (“9.8%, 0%) energy) at Day 90 compared with low-cal participants (0 (0, 173)) kcal/d, P = .02; 0 (0, 3.7%) energy, P = .02). The results suggest that following a vegan diet can be more effective for achieving weight loss in addition to better nutrient intake profile in women with PCOS; however, a bigger sample size is required to validate these results.

Effectiveness, Compliance, and Acceptability of Preoperative Weight Loss with a Liquid Very Low-Calorie Diet Before Bariatric Surgery in Real Practice

2018 ◽  
Vol 29 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Kamthorn Yolsuriyanwong ◽  
Komdej Thanavachirasin ◽  
Kimberly Sasso ◽  
Lauren Zuro ◽  
Jessica Bartfield ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Preoperative Weight Loss ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet ◽  
Preoperative Weight ◽  
Real Practice

scholarly journals Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

BMJ Open ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. e031431
Author(s):  
Simon Birk Kjær Jensen ◽  
Julie Rehné Lundgren ◽  
Charlotte Janus ◽  
Christian Rimer Juhl ◽  
Lisa Møller Olsen ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Receptor Agonist ◽  
Controlled Trial ◽  
Good Clinical Practice ◽  
Study Groups ◽  
Very Low Calorie Diet ◽  
Low Calorie ◽  
Low Calorie Diet ◽  
Calorie Diet

IntroductionThe success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.Methods and analysisThis is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18–65 years) with obesity (body mass index 32–43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.Ethics and disseminationThe trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.Trial registration number2015-005585-32

Sign in / Sign up

Export Citation Format

Share Document